| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
LivaNova PLC (NASDAQ: LIVN)
LIVN Technical Analysis
5
| As on 9th Jun 2023 LIVN STOCK Price closed @ 47.43 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 66.74 & Strong Sell for SHORT-TERM with Stoploss of 79.23 we also expect STOCK to react on Following IMPORTANT LEVELS. |
LIVNSTOCK Price
| Open | 47.40 | Change | Price | % |
| High | 47.63 | 1 Day | -0.05 | -0.11 |
| Low | 46.67 | 1 Week | 3.41 | 7.75 |
| Close | 47.43 | 1 Month | -0.51 | -1.06 |
| Volume | 223445 | 1 Year | -32.73 | -40.83 |
| 52 Week High 87.80 | 52 Week Low 40.84 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| LIVN Daily Charts |
LIVN Intraday Charts |
Whats New @ Bazaartrend |
LIVN Free Analysis |
|
|
LIVN Important Levels Intraday
| RESISTANCE | 49.28 |
| RESISTANCE | 48.69 |
| RESISTANCE | 48.32 |
| RESISTANCE | 47.95 |
| SUPPORT | 46.91 |
| SUPPORT | 46.54 |
| SUPPORT | 46.17 |
| SUPPORT | 45.58 |
LIVN Forecast May 2024
| 4th UP Forecast | 84.35 |
| 3rd UP Forecast | 72.51 |
| 2nd UP Forecast | 65.19 |
| 1st UP Forecast | 57.87 |
| 1st DOWN Forecast | 36.99 |
| 2nd DOWN Forecast | 29.67 |
| 3rd DOWN Forecast | 22.35 |
| 4th DOWN Forecast | 10.51 |
LIVN Weekly Forecast
| 4th UP Forecast | 61.50 |
| 3rd UP Forecast | 56.99 |
| 2nd UP Forecast | 54.20 |
| 1st UP Forecast | 51.41 |
| 1st DOWN Forecast | 43.45 |
| 2nd DOWN Forecast | 40.66 |
| 3rd DOWN Forecast | 37.87 |
| 4th DOWN Forecast | 33.36 |
LIVN Forecast2024
| 4th UP Forecast | 142.68 |
| 3rd UP Forecast | 112.13 |
| 2nd UP Forecast | 93.25 |
| 1st UP Forecast | 74.37 |
| 1st DOWN Forecast | 20.49 |
| 2nd DOWN Forecast | 1.61 |
| 3rd DOWN Forecast | -17.27 |
| 4th DOWN Forecast | -47.82 |
LivaNova PLC ( NASDAQ USA Symbol : LIVN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
LIVN Business Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom. Address: 20 Eastbourne Terrace, London, United Kingdom, W2 6LG
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service